RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 601–700 of 999
Recent developments related to the EGFR as a target for cancer chemotherapy
Speake, G., Holloway, B. R., & Costello, G. F. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.02.007 · Cited by 32
Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer
Marchoudi, N., Joutei, H. A. H., Jouali, F., Fekkak, J., & Rhaissi, H. (2013) · Pathologie Biologie · doi:10.1016/j.patbio.2013.05.004 · Cited by 32
Molecular targets and biological modifiers in gastric cancer
Carneiro, F., Oliveíra, C., Leite, M., & Seruca, R. (2008) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2008.07.004 · Cited by 31
Ooki, A., Akagi, K., Yatsuoka, T., Asayama, M., Hara, H., Takahashi, A., Kakuta, M., Nishimura, Y., & Yamaguchi, K. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23755 · Cited by 33
Ichimanda, M., Hijiya, N., Tsukamoto, Y., Uchida, T., Nakada, C., Akagi, T., Etoh, T., Iha, H., Inomata, M., Takekawa, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13444 · Cited by 33
“Somatic mutation of KRAS, NRAS, or BRAF, which is involved in the MAPK signaling pathway, has frequently been found in CRCs.(15,16) In addition to these mutations, EGFR overexpression detected in a smaller proportion of CRCs is also involved in MAPK signaling,(17) suggesting its importance in the development of CRCs.”
BackgroundInfluentialde la Fouchardière, C., Cohen, R., Malka, D., Guimbaud, R., Bourien, H., Lièvre, A., Cacheux, W., Artru, P., François, É., Gilabert, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0914 · Cited by 36
Genetic and epigenetic changes in colon cancer
Samowitz, W. S. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.03.008 · Cited by 31
A Modified Lynch Syndrome Screening Algorithm in Colon Cancer
Roth, R. M., Hampel, H., Arnold, C. A., Yearsley, M., Marsh, W. L., Jr., & Frankel, W. L. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp4d7rxobhlkgj · Cited by 33
Bianchi, A. S., Bencardino, K. B., Nicolantonio, F. D., Pozzi, F., Funaioli, C., Gambi, V., Arena, S., Martini, M., Lamba, S., Cassingena, A., et al. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0138-5 · Cited by 34
“Of note, KRAS and BRAF mutations are known to be mutually exclusive in CRC [ 11 ].”
BackgroundSelf-citationmiR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential
Meyer, S. E., Muench, D. E., Rogers, A. M., Newkold, T. J., Orr, E., O'Brien, E. J., Perentesis, J. P., Doench, J. G., Lal, A., Morris, P. J., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171312 · Cited by 31
“, 2013), Braf (Rajagopalan et al., 2002), Cdk12 (Blazek et al.”
Satorres, C., García‐Campos, M., & Bustamante, M. (2020) · Gut and Liver · doi:10.5009/gnl19402 · Cited by 41
“org will be an MSS.(6,7,20,32) Therefore, most sporadic MSI CRCs will exhibit a CIMP phenotype, but on the contrary not all CIMP tumors will express MLH1 methylation.”
BackgroundInfluentialRAS/RAF mutation and defective DNA mismatch repair in endometrial cancers
Mutch, D. G., Powell, M. A., Mallon, M. A., & Goodfellow, P. J. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.01.017 · Cited by 31
Molecular Diagnostics in Colorectal Carcinoma
Bhalla, A., Zulfiqar, M., & Bluth, M. H. (2018) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2018.02.008 · Cited by 34
Beaudry, K., Langlois, M., Montagne, A., Cagnol, S., Carrier, J. C., & Rivard, N. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27420 · Cited by 30
“…and CRC. Notably, mutations in genes encoding KRAS and BRAF, the upstream activators of ERK1/2 kinases. occur in approximately 40% and 10%, respectively, of all CRCs (Andreyev, Norman, Clarke, Cunningham, & Oates, 1998; Davies et al., 2002; Rajagopalan et al., 2002; Samowitz et al., 2000).”
BackgroundKim, C. J., Lee, J. H., Song, J. W., Cho, Y. G., Kim, S., Nam, S. W., Yoo, N. J., Park, W. S., & Lee, J. Y. (2007) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2007.02.007 · Cited by 37
Computational methods and resources for the interpretation of genomic variants in cancer
Tian, R., Basu, M. K., & Capriotti, E. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s8-s7 · Cited by 38
“for example, in the case of BRAF and KRAS (involved in RAS/RAF pathway) in colorectal cancer [97], APC and CTNNB1 (involved in beta catenin pathway) [98], EGFR and KRAS in lung adenocarcinomas [99], TP53 and MDM2 in many different cancer types [100].”
BackgroundRössle, M., Sigg, M., Rüschoff, J. H., Wild, P. J., Moch, H., Weber, A., & Rechsteiner, M. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1492-3 · Cited by 31
“V600E), which leads to a 10-fold increased kinase activity [8–10].”
BackgroundTherapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
Bianchi, A. S., Bencardino, K. B., Cassingena, A., Venturini, F., Funaioli, C., Cipani, T., Amatu, A., Pietrogiovanna, L., Schiavo, R., Nicolantonio, F. D., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70012-8 · Cited by 30
Self-citationkoochak, A., Rakhshani, N., Niya, M. H. K., Tameshkel, F. S., Sohrabi, M., Babaee, M. R., Rezvani, H., Bahar, B., Imanzade, F., Zamani, F., et al. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.2.603 · Cited by 32
“…gene create a constitutively active ras factor that leads to EGFR-independent activation of the MAPK signaling pathway (Bos et al., 1987; Bamford et al., 2004) and subsequent induces cell growth and resistance to apoptosis (Rajagopalan et al., 2002; Benvenuti et al., 2007; Schubbert et al., 2007).”
BackgroundResultInfluentialChen, K., Xia, G., Zhang, C., & Sun, Y. (2015) · Europe PMC (PubMed Central) · Cited by 31
Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment
Verdaguer, H., Saurí, T., & Macarulla, T. M. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.15 · Cited by 36
“BRAF mutations are associated with MSI; in sporadic CRC, BRAF mutations are found in about 40% to 60% of MSI tumors, compared to in only approximately 5% to 10% of microsatellite stable tumors (23).”
BackgroundContext-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth
Hao, H., Muniz-Medina, V. M., Mehta, H., Thomas, N. E., Khazak, V., Der, C. J., & Shields, J. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0728 · Cited by 30
Coulombe, G., & Rivard, N. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.11.001 · Cited by 36
Anwar, A., Uddin, N., Siddiqui, B. S., Siddiqui, R. A., Begum, S., & Choudhary, M. I. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4294-5 · Cited by 30
Biomarkers in Early-Stage Colorectal Cancer: Ready for Prime Time?
Church, D. N., Midgley, R. S., & Kerr, D. J. (2012) · Digestive Diseases · doi:10.1159/000341890 · Cited by 30
Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer
Mattos‐Arruda, L. D., Dienstmann, R., & Tabernero, J. M. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.030 · Cited by 35
Yang, Y., Wang, D., Jin, L., Wu, G., Bai, Z., Wang, J., Yao, H., & Zhang, Z. (2018) · Cancer Management and Research · doi:10.2147/cmar.s169649 · Cited by 31
Erve, I. V. ’., Greuter, M. J. E., Bolhuis, K., Vessies, D. C. L., Leal, A., Vink, G. R., van den Broek, D. A., Velculescu, V. E., Punt, C. J. A., Meijer, G. A., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.09.002 · Cited by 33
Self-citationElevation of thyroid cancer risk among cutaneous melanoma survivors
Goggins, W. B., Daniels, G. H., & Tsao, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21300 · Cited by 30
“For instance, in colon cancer, BRAFV600E mutations are seen more commonly in mismatch repair-deficient cancers compared to mismatch repaircompetent tumors.(15) A characteristic feature of mismatch repair compromise is microsatellite instability (MSI).”
BackgroundMolecular profile of colorectal cancer in Indonesia: is there another pathway?
Abdullah, M., Sudoyo, A. W., Utomo, A. R. H., Fauzi, A., & Rani, A. A. (2012) · Gastroenterology and hepatology from bed to bench. · Cited by 29
Köbel, M., Pohl, G., Schmitt, W., Hauptmann, S., Wang, T., & Shih, I. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62059-7 · Cited by 29
Kim, R. Y., Xu, H., Myllykangas, S., & Ji, H. P. (2011) · Personalized Medicine · doi:10.2217/pme.11.16 · Cited by 31
β-Catenin Mutations: Insights into the APC Pathway and the Power of Genetics
Morin, P. J., Kinzler, K. W., & Sparks, A. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2387 · Cited by 28
Self-citationYoshitake, R., Saeki, K., Eto, S., Shinada, M., Nakano, R., Sugiya, H., Endo, Y., Fujita, N., Nishimura, R., & Nakagawa, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-64832-5 · Cited by 33
He, K., Wang, Y., Zhong, Y., Pan, X., Si, L., & Lu, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s279312 · Cited by 30
Kundu, S., Ali, M. A., Handin, N., Conway, L. P., Rendo, V., Artursson, P., He, L., Globisch, D., & Sjöblom, T. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02025-2 · Cited by 34
The Adroitness of Andrographolide as a Natural Weapon Against Colorectal Cancer
Paul, S., Roy, D., Pati, S., & Sa, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731492 · Cited by 31
“Similarly, BRAF mutations activate BRAF serine-threonine kinase activity, consequently activate MAPK signaling cascade (Rajagopalan et al., 2002).”
BackgroundMutational Analysis of the BRAF Gene in Transitional Cell Carcinoma of the Bladder
Boulalas, I., Zaravinos, A., Delakas, D., & Spandidos, D. A. (2009) · The International Journal of Biological Markers · doi:10.5301/jbm.2009.4457 · Cited by 54
“Additionally, BRAF mutations such as the V600E were described in KRAS-negative colon carcinomas, suggesting that BRAF/KRAS-activating mutations are alternative genetic events in colon cancer (5-7).”
BackgroundResultPrognostic biomarkers in colorectal cancer: where do we stand?
Sagaert, X. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1532-z · Cited by 33
“BRAF is serine–threonine protein kinase that acts downstream of the KRAS signaling pathway [109].”
BackgroundTargeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer
Ai, X., Wu, Y., Zhang, W., Zhang, Z., Jin, G.-N., Zhao, J., Yu, J., Lin, Y., Zhang, W., Liang, H., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26427 · Cited by 33
“Kras is known to be overactivated in approximately 35% of sporadic colorectal cancer, leading to the hyperactivation of mitogen-activated protein kinases (MAPK) cascade, which then cooperates with TGF-β to promote CRC liver metastasis.(15,16) Therefore, we speculated that TGF-β may activate Smad-independent ERK pathwa…”
BackgroundHigh sensitivity EndoV mutation scanning through real-time ligase proofreading
Pinças, H. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh150 · Cited by 28
“For example, the current list of biologically important genes for colon cancer include APC, b-catenin (3,5), K-ras (2), B-raf (7,65), p53 (66), PI3KCA (8), hCDC4 (67), Tyr kinases (9), phosphatases (10), BAX, TGFBRII and TCF4 (1,6,5).”
BackgroundMicrosatellite Instability and Adjuvant Fluorouracil Chemotherapy: A Mismatch?
Ng, K., & Schrag, D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9314 · Cited by 31
Kras in metastatic colorectal cancer
WICKI, A. N., Herrmann, R., & Christofori, G. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13112 · Cited by 34
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
Nguyen, T. K., Jordan, N., Friedberg, J. W., Fisher, R. I., Dent, P., & Grant, S. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.07.013 · Cited by 30
Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours
Velho, S., Oliveíra, C., Paredes, J., Sousa, S., Leite, M., Matos, P., Milanezi, F., Ribeiro, A. S., Mendes, N. M., Licastro, D., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp536 · Cited by 28
“Human Molecular Genetics, 2010, Vol. 19, No. 4 tumours (1,3–5,18,19), although MAPK activation is reported to occur in over 70% of overall CRC cases (22).”
BackgroundInfluentialFrequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma
Idrees, K., Padmanabhan, C., Liu, E. V., Guo, Y. P., González, R. S., Berlin, J. D., Dahlman, K. B., Beauchamp, R. D., & Shi, C. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24834 · Cited by 28
“RAF and RASmutations have been shown to bemutually exclusive in colorectal adenocarcinomas and BRAF mutations have been associated with microsatellite unstable tumors.(23) Three of the four BRAF mutated cases in our series were definitively KRAS and NRAS wild-type and one case (S6) was NRAS wild-type but inconclusive…”
BackgroundGenomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer
Meng, H., Guo, X., Sun, D., Liang, Y., Lang, J., Han, Y., Lu, Q., Zhang, Y., An, Y., Tian, G., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01008 · Cited by 31
Capicua suppresses colorectal cancer progression via repression of ETV4 expression
Lee, J.-S., Kim, E., Lee, J., Kim, D., Kim, H., Kim, C.-J., Kim, S., Jeong, D., & Lee, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1111-8 · Cited by 33
Buchmann, A., Karcier, Z., Schmid, B., Strathmann, J., & Schwarz, M. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2007.08.015 · Cited by 29
Fedorov, L. M., Papadopoulos, T., Tyrsin, O. Y., Twardzik, T., Götz, R., & Rapp, U. R. (2003) · PubMed · Cited by 28
Weickhardt, A. J., Tebbutt, N. C., & Mariadason, J. M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357961 · Cited by 27
“Activating mutations in BRAF affect the MAPK signalling pathway and occur in a mutually exclusive manner with K-Ras mutations in colon cancer [22].”
BackgroundAnbar, H. S., El-Gamal, M. I., Tarazi, H., Lee, B. S., Jeon, H. R., Kwon, D., & Oh, C. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1819260 · Cited by 27
BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications
Angerilli, V., Sabella, G., Centonze, G., Lonardi, S., Bergamo, F., Mangogna, A., Pietrantonio, F., Fassan, M., & Milione, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103647 · Cited by 30
Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models
Matsuo, T., Nishizuka, S., Ishida, K., Iwaya, T., Ikeda, M., & Wakabayashi, G. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-140 · Cited by 30
“This is in agreement with previously published observations by other authors that mutations in KRAS and BRAF are mutually exclusive [20,21].”
ResultBRAF Polymorphisms and Risk of Melanocytic Neoplasia
James, M. R., Roth, R. B., Shi, M. M., Kammerer, S., Nelson, M. R., Stark, M. S., Dumenil, T. D., Montgomery, G. W., Hayward, N. K., Martin, N. G., et al. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23937.x · Cited by 27
内山, 美., Usami, N., Kondo, M., Mori, S., Ito, M., Ito, G., Yoshioka, H., Imaizumi, M., Ueda, Y., Takahashi, M., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11493 · Cited by 27
Clinical implications of BRAF mutation test in colorectal cancer.
Mojarad, E. N., Farahani, R. K., Haghighi, M. M., Aghdaei, H. A., Kuppen, P. J. K., & Zali, M. R. (2013) · Gastroenterology and hepatology from bed to bench. · Cited by 27
Sex Difference of Colon Adenoma Pathway and Colorectal Carcinogenesis
Choi, Y., & Kim, N. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.230085 · Cited by 39
Miglio, U., Mezzapelle, R., Paganotti, A., Allegrini, S., Veggiani, C., Antona, J., Gentilli, S., Monga, G., Alabiso, O., & Boldorini, R. L. (2013) · Pathology - Research and Practice · doi:10.1016/j.prp.2013.02.006 · Cited by 28
Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia
Zhang, X., Reis, M. M., Khoriaty, R. N., Li, Y., Ouillette, P. D., Samayoa, J. A., Carter, H., Karchin, R., Li, M., Diaz, L. A., et al. (2011) · Leukemia · doi:10.1038/leu.2011.163 · Cited by 29
Self-citationIJspeert, J. E. G., Medema, J. P., & Dekker, E. (2015) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2014.11.004 · Cited by 34
Siegmund, S., Manning, D. K., Davineni, P. K., & Dong, F. (2022) · Modern Pathology · doi:10.1038/s41379-022-01083-x · Cited by 27
KRAS and BRAF mutations in prostate carcinomas of Chinese patients
Shen, Y., Lu, Y., Yin, X., Zhu, G., & Jianshan, Z. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.12.003 · Cited by 26
Identification of cancer genes by mutational profiling of tumor genomes
Benvenuti, S., Arena, S., & Bardelli, A. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.02.015 · Cited by 28
“They started by analyzing all the members of the RAS–RAF–MEK–ERK–MAP kinase pathway [5,28].”
BackgroundSelf-citationFrom Oncogene to Network Addiction: The New Frontier of Cancer Genomics and Therapeutics
Tonon, G. (2008) · Future Oncology · doi:10.2217/14796694.4.4.569 · Cited by 29
“Melanomas [57] and colon cancers [58] frequently present mutually exclusive mutations in these two genes, suggesting the involvement of the same pathway, by different means.”
BackgroundYu, M., & Grady, W. M. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12448456 · Cited by 26
BRAF mutation detection and identification by cycling temperature capillary electrophoresis
Hinselwood, D. C., Abrahamsen, T. W., & Ekstrøm, P. O. (2005) · Electrophoresis · doi:10.1002/elps.200410427 · Cited by 26
Serrated polyps: critical precursors to colorectal cancer
Sweetser, S. R., Smyrk, T. C., & Sugumar, A. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.67 · Cited by 26
Mutational and co-mutational landscape of early onset colorectal cancer
Alshenaifi, J. Y., Vetere, G., Maddalena, G., Yousef, M., White, M. G., Shen, J. P., Vilar, E., Parseghian, C. M., Dasari, A., Morris, V. K., et al. (2025) · Biomarkers · doi:10.1080/1354750x.2024.2447089 · Cited by 25
“Driver mutations and genetic alterations are fundamental to the pathophysiology of cRc, providing tumor cells with a growth advantage crucial for cancer development and dissemination (cho & Vogelstein, 1992; Rajagopalan et al., 2002; Vogelstein et al., 2013).”
Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
Mirone, G., Shukla, A. K., & Marfè, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.012 · Cited by 32
Kristensen, L. S., Andersen, G. B., Hager, H., & Hansen, L. L. (2011) · Human Mutation · doi:10.1002/humu.21598 · Cited by 26
“Activating mutations in KRAS and BRAF are found in approximately 40–50% and 10–15% of CRC patients, respectively, and found to be mutually exclusive [Rajagopalan et al., 2002].”
BackgroundJeong, W.-J., Cha, P.-H., & Choi, K.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9862 · Cited by 27
Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
Bond, C., Umapathy, A., Buttenshaw, R. L., Wockner, L. F., Leggett, B., & Whitehall, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047483 · Cited by 25
“Patient Samples 1052 sporadic CRC and matched normal mucosa samples were obtained after surgical excision at the Royal Brisbane and Women’s Hospital (RBWH), Queensland, Australia.”
BackgroundInfluentialBRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
Chen, K.-H., Lin, Y., Liau, J., Tsai, J., Tseng, L., Lin, L., Liang, J., Lin, B., Hung, J., Chang, Y., et al. (2016) · Medical Oncology · doi:10.1007/s12032-016-0756-6 · Cited by 25
El‐Damasy, A. K., Cho, N., Nam, G., Pae, A. N., & Keum, G. (2016) · ChemMedChem · doi:10.1002/cmdc.201600224 · Cited by 25
Recent advances in B-RAF inhibitors as anticancer agents
Khan, P. S., Rajesh, P., Rajendra, P., Chaskar, M. G., Arote, R. B., & Sangshetti, J. N. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105597 · Cited by 27
Lee, C., Lee, M. E., Lee, W. S., Kim, J., Park, K.-H., Kim, T. S., Lee, K. Y., Ahn, J. B., Chung, H. C., & Rha, S. Y. (2015) · Europe PMC (PubMed Central) · Cited by 29
DNA Methylation Changes in Cancer
Toyota, M., & Yamamoto, E. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-387685-0.00014-7 · Cited by 26
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
Jakovljevic, K., Malisic, E. J., Cavic, M., Krivokuća, A., Dobričić, J., & Jankovic, R. N. (2012) · PubMed · Cited by 27
RNA interference as an anticancer therapy: a patent perspective
Dykxhoorn, D. M. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902838008 · Cited by 29
“Similar to RAS, many human malignancies including melanomas, colon, thyroid, papillary and ovarian tumors contain mutation in RAF that render it constitutively active [53,54].”
BackgroundChen, C. Y., & Tang, H. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80150 · Cited by 34
“24,25 Primary resistance includes loss or inactivation of essential tumor suppressors.”
Ng, M. H. L., Lau, K., Wong, W. S., To, K. W., Cheng, S. H., Tsang, K. S., Chan, N. P. H., Kho, B., Lo, K. W., TONG, J. H. M., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04664.x · Cited by 25
“B-Ras associated factor (BRAF) is a member of the RAF family, which codes for kinases that are regulated by binding Ras-p21 and mediates cellular response to growth signals (Davies et al, 2002; Rajagopalan et al, 2002).”
BackgroundResultInfluentialRKIP and BRAF aberrations in human nasal polyps and the adjacent turbinate mucosae
Zaravinos, A., Bizakis, J. G., & Spandidos, D. A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.01.046 · Cited by 25
Miyaki, M., Iijima, T., Yamaguchi, T., Kadofuku, T., Funata, N., & Mori, T. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.01.027 · Cited by 25
BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias
Davidsson, J., Lilljebjörn, H., Panagopoulos, I., Fioretos, T., & Johansson, B. (2008) · Leukemia · doi:10.1038/leu.2008.14 · Cited by 25
Ballestrero, A., Garuti, A., Cirmena, G., Rocco, I., Palermo, C., Nencioni, A., Scabini, S., Zoppoli, G. M., Parodi, S., & Patrone, F. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912800190956 · Cited by 25
“Because KRAS and BRAF mutations are mutually exclusive in mCRCs [38] BRAF mutated tumors can be added to those with KRAS mutations”
BackgroundProgrammed death 1 blockade, an Achilles heel for MMR-deficient tumors?
Lin, A. Y., & Lin, E. H. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0222-5 · Cited by 26
“B-raf mutation is linked to the MMR deficiency of these tumors in repairing mismatched bases in DNA and is associated with poor prognosis in colorectal cancer [28].”
BackgroundRodrigues, D., Longatto‐Filho, A., & Martins, S. F. F. (2016) · BioMed Research International · doi:10.1155/2016/6896024 · Cited by 27
SerpinB3 upregulates the Cyclooxygenase-2 / β-Catenin positive loop in colorectal cancer
Terrin, L., Agostini, M., Ruvoletto, M., Martini, A., Pucciarelli, S., Bedin, C., Nitti, D., & Pontisso, P. (2017) · Oncotarget · doi:10.18632/oncotarget.14997 · Cited by 26
Molecular Diagnostics in Colorectal Carcinoma
Bhalla, A., Zulfiqar, M., Weindel, M., & Shidham, V. B. (2013) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.10.001 · Cited by 25
Reduced expression of RAS protein activator like‐1 in gastric cancer
Seto, M., Ohta, M., Ikenoue, T., Sugimoto, T., Asaoka, Y., Tada, M., Mohri, D., Kudo, Y., Ijichi, H., Tateishi, K., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25459 · Cited by 29
Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice
Jiang, W., Fu, F.-F., Li, Y.-X., Wang, W., Wang, H., Jiang, H., & Teng, L. (2012) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1100340 · Cited by 26
“BRAF mutations in CRC have been reported to occur more frequently in cases characterized by the presence of dMMR and to confer a poor prognosis (Rajagopalan et al., 2002; Roth et al., 2010).”
Faro, A., Boj, S. F., & Clevers, H. C. (2009) · Zebrafish · doi:10.1089/zeb.2009.0617 · Cited by 27
Iijima, M., Banno, K., Okawa, R., Yanokura, M., Iida, M., Takeda, T., Irie, H., Adachi, M., Nakamura, K., Umene, K., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5582 · Cited by 31
“BRAF mutations may occur in patients without concurrent KRAS mutations, in various types of cancer, which suggests that KRAS and BRAF have complementary functions in the activation of the mitogen-activated protein kinase (MAPK) signaling pathway (49).”
Li, Y., & Li, Y. (2017) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.207712 · Cited by 24
“The prevalence of BRAF mutation in MMR‐deficient tumors has been shown to be three‐fold greater than in MMR‐proficient tumors.[39]”
BackgroundGrassinger, J. M., Merz, S. E., Aupperle‐Lellbach, H., Erhard, H., & Klopfleisch, R. (2019) · Veterinary Sciences · doi:10.3390/vetsci6010031 · Cited by 24
“It is frequently mutated in melanomas (50%) [34], papillary thyroid cancers (45%) [35], colon cancers (10%) [36], and in non-small-cell lung cancers (10%) [37].”
BackgroundSystemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer
Chavda, J., & Bhatt, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112675 · Cited by 25
Bentivegna, S., Zheng, J., Namsaraev, E. A., Carlton, V. E. H., Pavlı́ček, A., Moorhead, M., Siddiqui, F. A., Wang, Z., Lee, L., Ireland, J. S., et al. (2008) · Human Mutation · doi:10.1002/humu.20672 · Cited by 24
“Previous large surveys of colorectal tumors have found a statistically significant absence of KRAS/BRAF double mutants [Rajagopalan et al., 2002; Nagasaka et al., 2004].”
Research progress of DNA methylation in colorectal cancer (Review)
Wang, Y., Wang, C., Zhong, R., Wang, L., & Sun, L. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13278 · Cited by 31
“When the KRAS gene is mutated, it is permanently activated and cannot produce normal RAS protein, leading to intracellular signal transduction error, rampant cell proliferation and canceration (18).”
BackgroundAssociation Between Smoking and Molecular Subtypes of Colorectal Cancer
Wang, X., Amitay, E. L., Harrison, T. A., Banbury, B. L., Berndt, S. I., Brenner, H., Buchanan, D. D., Campbell, P. T., Cao, Y., Chan, A. T., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab056 · Cited by 23
“CIMP+ CRC tumors tend to have a high frequency of MSI and BRAF mutation [9, 31-34].”
Background
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.